The global rheumatoid arthritis therapeutics market size is expected to reach USD 36.39 billion by 2030, expanding at a CAGR of 5.93% from 2024 to 2030, according to a new study. expanding at a CAGR of 4.6% during the forecast period. Some of the key trends driving the market are availability of novel biologics, increase in potential clinical pipeline candidates, and rise in aging population. Thus, growing availability and awareness of safer drugs are projected to escalate rheumatoid arthritis drugs market growth. ![Rheumatoid Arthritis Therapeutics Market]( "Rheumatoid Arthritis Therapeutics Market")
Rheumatoid arthritis affects approximately 1% of the global population. The condition has different symptoms such as joint pain, swelling, and stiffness, which are generally accompanied by chronic pain and inability to perform daily activities. Over a prolonged period, this disorder can hamper a patient's mobility and can lead to permanent joint damage. If left untreated, this disorder can lead to mobility impairment and risk of joint replacement.
Growing prevalence of the disease, presence of biologics & biosimilars, and well-defined regulatory guidelines are poised to provide a fillip to the market. According to the Arthritis Foundation, 64% of the population within the age group of 65 is likely to suffer from arthritis in U.S. Increasing awareness regarding disease remittance therapies and rising healthcare expenditure in developed regions are estimated to promote revenue growth.
Current treatment for rheumatoid arthritis includes generic pharmaceuticals such as NSAIDs and corticosteroids along with novel biologics such as JAK inhibitors and IL-6 antagonists, which are widely used in developed countries due to their high effectiveness. New product launches such as Infliximab and Adalimumab biosimilars are anticipated to work in favor of the market. Moreover, Eli Lilly's Olumiant and AbbVie's Upadacitinib are expected to cut down chances of disease remittance.
Rheumatoid arthritis affects approximately 1% of the global population. The condition has different symptoms such as joint pain, swelling, and stiffness, which are generally accompanied by chronic pain and inability to perform daily activities. Over a prolonged period, this disorder can hamper a patient's mobility and can lead to permanent joint damage. If left untreated, this disorder can lead to mobility impairment and risk of joint replacement.
Growing prevalence of the disease, presence of biologics & biosimilars, and well-defined regulatory guidelines are poised to provide a fillip to the market. According to the Arthritis Foundation, 64% of the population within the age group of 65 is likely to suffer from arthritis in U.S. Increasing awareness regarding disease remittance therapies and rising healthcare expenditure in developed regions are estimated to promote revenue growth.
Current treatment for rheumatoid arthritis includes generic pharmaceuticals such as NSAIDs and corticosteroids along with novel biologics such as JAK inhibitors and IL-6 antagonists, which are widely used in developed countries due to their high effectiveness. New product launches such as Infliximab and Adalimumab biosimilars are anticipated to work in favor of the market. Moreover, Eli Lilly's Olumiant and AbbVie's Upadacitinib are expected to cut down chances of disease remittance.
Rheumatoid Arthritis Therapeutics Market Report Highlights
- Biopharmaceuticals segment led the market and accounted for 88.73% of the global revenue in 2023. Biopharmaceuticals are large-molecule drugs that are manufactured, extracted, and synthesized from biological sources.
- Prescription led the market with a market share of 89.64% in 2023. As rheumatologist consultations rise, the prescription segment is expected to remain dominant in the market for rheumatoid arthritis medications over the forecast period.
- North America rheumatoid arthritis therapeutics market accounted for 52.31% share in 2023. The regional market continues to grow and evolve, driven by demographic shifts, advancements in medical research, regulatory changes, and an increasing emphasis on personalized healthcare.
- The Asia Pacific rheumatoid arthritis therapeutics market is experiencing significant growth, driven by the increasing prevalence of rheumatoid arthritis, improving healthcare infrastructure, and advancements in treatment options.
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Molecule
1.2.2. Sales channel
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. Internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
1.2. Segment Definitions
1.2.1. Molecule
1.2.2. Sales channel
1.2.3. Regional scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. Internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Molecule and Sales Channel Segment Snapshot
2.3. Competitive Landscape Snapshot
2.2. Molecule and Sales Channel Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Rheumatoid Arthritis Therapeutics Market Variables, Trends, and Scope
3.1. Rheumatoid Arthritis Therapeutics Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Ancillary market outlook - Osteoarthritis Therapeutics Market
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing prevalence of rheumatoid arthritis
3.2.1.2. Launch of novel therapeutic agents
3.2.1.3. Shift in treatment from the relief of symptoms to targeted therapy
3.2.1.4. Favorable reimbursement policies
3.2.2. Market Restraint Analysis
3.2.2.1. High cost of rheumatoid arthritis therapeutic drugs
3.2.2.2. Side effects and adverse reactions
3.3. Rheumatoid Arthritis Therapeutics Market Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTLE Analysis
3.1.1. Parent Market Outlook
3.1.2. Ancillary market outlook - Osteoarthritis Therapeutics Market
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing prevalence of rheumatoid arthritis
3.2.1.2. Launch of novel therapeutic agents
3.2.1.3. Shift in treatment from the relief of symptoms to targeted therapy
3.2.1.4. Favorable reimbursement policies
3.2.2. Market Restraint Analysis
3.2.2.1. High cost of rheumatoid arthritis therapeutic drugs
3.2.2.2. Side effects and adverse reactions
3.3. Rheumatoid Arthritis Therapeutics Market Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTLE Analysis
Chapter 4. Rheumatoid Arthritis Therapeutics Market Analysis, by Molecule, 2018 - 2030 (USD Million)
4.1. Rheumatoid Arthritis Therapeutics: Molecule Movement Analysis
4.2. Rheumatoid Arthritis Therapeutics Market Analysis, by Molecule Market (USD Million)
4.2.1. Biopharmaceuticals
4.2.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.2. Biologics
4.2.1.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.2.2. TNF-a antagonists
4.2.1.2.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.2.3. T-cell inhibitors
4.2.1.2.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.2.4. CD20 antigen
4.2.1.2.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.2.5. JAK inhibitors
4.2.1.2.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.2.6. anti-IL6 biologics
4.2.1.2.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.3. Biosimilars
4.2.1.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.3.2. CD20 antigen
4.2.1.3.3. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.3.4. TNF-a antagonists
4.2.1.3.5. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.2. Pharmaceuticals
4.2.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.2.2. NSAIDs
4.2.2.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.2.3. Analgesics
4.2.2.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.2.4. DMARDs
4.2.2.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.2.5. Glucocorticoids
4.2.2.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2. Rheumatoid Arthritis Therapeutics Market Analysis, by Molecule Market (USD Million)
4.2.1. Biopharmaceuticals
4.2.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.2. Biologics
4.2.1.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.2.2. TNF-a antagonists
4.2.1.2.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.2.3. T-cell inhibitors
4.2.1.2.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.2.4. CD20 antigen
4.2.1.2.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.2.5. JAK inhibitors
4.2.1.2.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.2.6. anti-IL6 biologics
4.2.1.2.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.3. Biosimilars
4.2.1.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.3.2. CD20 antigen
4.2.1.3.3. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.1.3.4. TNF-a antagonists
4.2.1.3.5. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.2. Pharmaceuticals
4.2.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.2.2. NSAIDs
4.2.2.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.2.3. Analgesics
4.2.2.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.2.4. DMARDs
4.2.2.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.2.2.5. Glucocorticoids
4.2.2.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Rheumatoid Arthritis Therapeutics Market Analysis, by Sales Channel, 2018 - 2030 (USD Million)
5.1. Rheumatoid Arthritis Therapeutics: Sales Channel Movement Analysis
5.2. Rheumatoid Arthritis Therapeutics Market Analysis, by Sales Channel Market (USD Million)
5.2.1. Prescription
5.2.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.2. Over-the-Counter (OTC)
5.2.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2. Rheumatoid Arthritis Therapeutics Market Analysis, by Sales Channel Market (USD Million)
5.2.1. Prescription
5.2.1.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.2.2. Over-the-Counter (OTC)
5.2.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Rheumatoid Arthritis Therapeutics Market: Regional Estimates and Trend Analysis by Molecule, by Sales Channel
6.1. Rheumatoid Arthritis Therapeutics Market: Regional Outlook
6.2. North America
6.2.1. North America Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.2. U.S.
6.2.2.1. Key Country Dynamics
6.2.2.2. Target Disease Prevalence
6.2.2.3. U.S. Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.2.4. Competitive/Market Scenario
6.2.2.5. Regulatory Framework
6.2.2.6. Reimbursement scenario
6.2.3. Canada
6.2.3.1. Key Country Dynamics
6.2.3.2. Target Disease Prevalence
6.2.3.3. Canada Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.3.4. Competitive/Market Scenario
6.2.3.5. Regulatory Framework
6.2.3.6. Reimbursement Scenario
6.2.4. Mexico
6.2.4.1. Key Country Dynamics
6.2.4.2. Target Disease Prevalence
6.2.4.3. Mexico Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.4.4. Competitive/Market Scenario
6.2.4.5. Regulatory Framework
6.2.4.6. Reimbursement Scenario
6.3. Europe
6.3.1. Europe Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.2. UK
6.3.2.1. Key Country Dynamics
6.3.2.2. Target Disease Prevalence
6.3.2.3. UK Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.2.4. Competitive/Market Scenario
6.3.2.5. Regulatory Framework
6.3.2.6. Reimbursement Scenario
6.3.3. Germany
6.3.3.1. Key Country Dynamics
6.3.3.2. Target Disease Prevalence
6.3.3.3. Germany Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.3.4. Competitive/Market Scenario
6.3.3.5. Regulatory Framework
6.3.3.6. Reimbursement Scenario
6.3.4. France
6.3.4.1. Key Country Dynamics
6.3.4.2. Target Disease Prevalence
6.3.4.3. France Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.4.4. Competitive/Market Scenario
6.3.4.5. Regulatory Framework
6.3.4.6. Reimbursement Scenario
6.3.5. Spain
6.3.5.1. Key Country Dynamics
6.3.5.2. Target Disease Prevalence
6.3.5.3. Spain Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.5.4. Competitive/Market Scenario
6.3.5.5. Regulatory Framework
6.3.5.6. Reimbursement Scenario
6.3.6. Italy
6.3.6.1. Key Country Dynamics
6.3.6.2. Target Disease Prevalence
6.3.6.3. Italy Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.6.4. Competitive/Market Scenario
6.3.6.5. Regulatory Framework
6.3.6.6. Reimbursement Scenario
6.3.7. Denmark
6.3.7.1. Key Country Dynamics
6.3.7.2. Target Disease Prevalence
6.3.7.3. Denmark Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.7.4. Competitive/Market Scenario
6.3.7.5. Regulatory Framework
6.3.7.6. Reimbursement Scenario
6.3.8. Sweden
6.3.8.1. Key Country Dynamics
6.3.8.2. Target Disease Prevalence
6.3.8.3. Sweden Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.8.4. Competitive/Market Scenario
6.3.8.5. Regulatory Framework
6.3.8.6. Reimbursement Scenario
6.3.9. 6.3.9 Norway
6.3.9.1. Key Country Dynamics
6.3.9.2. Target Disease Prevalence
6.3.9.3. Norway Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.9.4. Competitive/Market Scenario
6.3.9.5. Regulatory Framework
6.3.9.6. Reimbursement Scenario
6.3.9.7. Rest of Europe Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Asia Pacific
6.4.1. Asia Pacific Rheumatoid Arthritis Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4.2. Japan
6.4.2.1. Key Country Dynamics
6.4.2.2. Target Disease Prevalence
6.4.2.3. Japan Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.2.4. Competitive/Market Scenario
6.4.2.5. Regulatory Framework
6.4.2.6. Reimbursement Scenario
6.4.3. China
6.4.3.1. Key Country Dynamics
6.4.3.2. Target Disease Prevalence
6.4.3.3. China Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.3.4. Competitive/Market Scenario
6.4.3.5. Regulatory Framework
6.4.3.6. Reimbursement Scenario
6.4.4. India
6.4.4.1. Key Country Dynamics
6.4.4.2. Target Disease Prevalence
6.4.4.3. India Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.4.4. Competitive/Market Scenario
6.4.4.5. Regulatory Framework
6.4.4.6. Reimbursement Scenario
6.4.5. Australia
6.4.5.1. Key Country Dynamics
6.4.5.2. Target Disease Prevalence
6.4.5.3. Australia Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.5.4. Competitive/Market Scenario
6.4.5.5. Regulatory Framework
6.4.5.6. Reimbursement Scenario
6.4.6. Thailand
6.4.6.1. Key Country Dynamics
6.4.6.2. Target Disease Prevalence
6.4.6.3. Thailand Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.6.4. Competitive/Market Scenario
6.4.6.5. Regulatory Framework
6.4.6.6. Reimbursement Scenario
6.4.7. South Korea
6.4.7.1. Key Country Dynamics
6.4.7.2. Target Disease Prevalence
6.4.7.3. South Korea Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.7.4. Competitive/Market Scenario
6.4.7.5. Regulatory Framework
6.4.7.6. Reimbursement Scenario
6.4.7.7. Rest of Asia Pacific Rheumatoid Arthritis Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.5. Latin America
6.5.1. Latin America Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.2. Brazil
6.5.2.1. Key Country Dynamics
6.5.2.2. Target Disease Prevalence
6.5.2.3. Brazil Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.2.4. Competitive/Market Scenario
6.5.2.5. Regulatory Framework
6.5.2.6. Reimbursement Scenario
6.5.3. Argentina
6.5.3.1. Key Country Dynamics
6.5.3.2. Target Disease Prevalence
6.5.3.3. Argentina Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.3.4. Competitive/Market Scenario
6.5.3.5. Regulatory Framework
6.5.3.6. Reimbursement Scenario
6.5.3.7. Rest of Latin America Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. MEA
6.6.1. MEA Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.2. South Africa
6.6.2.1. Key Country Dynamics
6.6.2.2. Target Disease Prevalence
6.6.2.3. South Africa Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.2.4. Competitive/Market Scenario
6.6.2.5. Regulatory Framework
6.6.2.6. Reimbursement Scenario
6.6.3. Saudi Arabia
6.6.3.1. Key Country Dynamics
6.6.3.2. Target Disease Prevalence
6.6.3.3. Saudi Arabia Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.3.4. Competitive/Market Scenario
6.6.3.5. Regulatory Framework
6.6.3.6. Reimbursement Scenario
6.6.4. UAE
6.6.4.1. Key Country Dynamics
6.6.4.2. Target Disease Prevalence
6.6.4.3. UAE Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.4.4. Competitive/Market Scenario
6.6.4.5. Regulatory Framework
6.6.4.6. Reimbursement Scenario
6.6.5. Kuwait
6.6.5.1. Key Country Dynamics
6.6.5.2. Target Disease Prevalence
6.6.5.3. Kuwait Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.5.4. Competitive/Market Scenario
6.6.5.5. Regulatory Framework
6.6.5.6. Reimbursement Scenario
6.6.6. Rest of MEA Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2. North America
6.2.1. North America Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.2. U.S.
6.2.2.1. Key Country Dynamics
6.2.2.2. Target Disease Prevalence
6.2.2.3. U.S. Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.2.4. Competitive/Market Scenario
6.2.2.5. Regulatory Framework
6.2.2.6. Reimbursement scenario
6.2.3. Canada
6.2.3.1. Key Country Dynamics
6.2.3.2. Target Disease Prevalence
6.2.3.3. Canada Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.3.4. Competitive/Market Scenario
6.2.3.5. Regulatory Framework
6.2.3.6. Reimbursement Scenario
6.2.4. Mexico
6.2.4.1. Key Country Dynamics
6.2.4.2. Target Disease Prevalence
6.2.4.3. Mexico Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.2.4.4. Competitive/Market Scenario
6.2.4.5. Regulatory Framework
6.2.4.6. Reimbursement Scenario
6.3. Europe
6.3.1. Europe Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.2. UK
6.3.2.1. Key Country Dynamics
6.3.2.2. Target Disease Prevalence
6.3.2.3. UK Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.2.4. Competitive/Market Scenario
6.3.2.5. Regulatory Framework
6.3.2.6. Reimbursement Scenario
6.3.3. Germany
6.3.3.1. Key Country Dynamics
6.3.3.2. Target Disease Prevalence
6.3.3.3. Germany Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.3.4. Competitive/Market Scenario
6.3.3.5. Regulatory Framework
6.3.3.6. Reimbursement Scenario
6.3.4. France
6.3.4.1. Key Country Dynamics
6.3.4.2. Target Disease Prevalence
6.3.4.3. France Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.4.4. Competitive/Market Scenario
6.3.4.5. Regulatory Framework
6.3.4.6. Reimbursement Scenario
6.3.5. Spain
6.3.5.1. Key Country Dynamics
6.3.5.2. Target Disease Prevalence
6.3.5.3. Spain Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.5.4. Competitive/Market Scenario
6.3.5.5. Regulatory Framework
6.3.5.6. Reimbursement Scenario
6.3.6. Italy
6.3.6.1. Key Country Dynamics
6.3.6.2. Target Disease Prevalence
6.3.6.3. Italy Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.6.4. Competitive/Market Scenario
6.3.6.5. Regulatory Framework
6.3.6.6. Reimbursement Scenario
6.3.7. Denmark
6.3.7.1. Key Country Dynamics
6.3.7.2. Target Disease Prevalence
6.3.7.3. Denmark Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.7.4. Competitive/Market Scenario
6.3.7.5. Regulatory Framework
6.3.7.6. Reimbursement Scenario
6.3.8. Sweden
6.3.8.1. Key Country Dynamics
6.3.8.2. Target Disease Prevalence
6.3.8.3. Sweden Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.8.4. Competitive/Market Scenario
6.3.8.5. Regulatory Framework
6.3.8.6. Reimbursement Scenario
6.3.9. 6.3.9 Norway
6.3.9.1. Key Country Dynamics
6.3.9.2. Target Disease Prevalence
6.3.9.3. Norway Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.3.9.4. Competitive/Market Scenario
6.3.9.5. Regulatory Framework
6.3.9.6. Reimbursement Scenario
6.3.9.7. Rest of Europe Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Asia Pacific
6.4.1. Asia Pacific Rheumatoid Arthritis Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.4.2. Japan
6.4.2.1. Key Country Dynamics
6.4.2.2. Target Disease Prevalence
6.4.2.3. Japan Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.2.4. Competitive/Market Scenario
6.4.2.5. Regulatory Framework
6.4.2.6. Reimbursement Scenario
6.4.3. China
6.4.3.1. Key Country Dynamics
6.4.3.2. Target Disease Prevalence
6.4.3.3. China Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.3.4. Competitive/Market Scenario
6.4.3.5. Regulatory Framework
6.4.3.6. Reimbursement Scenario
6.4.4. India
6.4.4.1. Key Country Dynamics
6.4.4.2. Target Disease Prevalence
6.4.4.3. India Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.4.4. Competitive/Market Scenario
6.4.4.5. Regulatory Framework
6.4.4.6. Reimbursement Scenario
6.4.5. Australia
6.4.5.1. Key Country Dynamics
6.4.5.2. Target Disease Prevalence
6.4.5.3. Australia Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.5.4. Competitive/Market Scenario
6.4.5.5. Regulatory Framework
6.4.5.6. Reimbursement Scenario
6.4.6. Thailand
6.4.6.1. Key Country Dynamics
6.4.6.2. Target Disease Prevalence
6.4.6.3. Thailand Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.6.4. Competitive/Market Scenario
6.4.6.5. Regulatory Framework
6.4.6.6. Reimbursement Scenario
6.4.7. South Korea
6.4.7.1. Key Country Dynamics
6.4.7.2. Target Disease Prevalence
6.4.7.3. South Korea Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.7.4. Competitive/Market Scenario
6.4.7.5. Regulatory Framework
6.4.7.6. Reimbursement Scenario
6.4.7.7. Rest of Asia Pacific Rheumatoid Arthritis Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
6.5. Latin America
6.5.1. Latin America Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.2. Brazil
6.5.2.1. Key Country Dynamics
6.5.2.2. Target Disease Prevalence
6.5.2.3. Brazil Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.2.4. Competitive/Market Scenario
6.5.2.5. Regulatory Framework
6.5.2.6. Reimbursement Scenario
6.5.3. Argentina
6.5.3.1. Key Country Dynamics
6.5.3.2. Target Disease Prevalence
6.5.3.3. Argentina Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.3.4. Competitive/Market Scenario
6.5.3.5. Regulatory Framework
6.5.3.6. Reimbursement Scenario
6.5.3.7. Rest of Latin America Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. MEA
6.6.1. MEA Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.2. South Africa
6.6.2.1. Key Country Dynamics
6.6.2.2. Target Disease Prevalence
6.6.2.3. South Africa Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.2.4. Competitive/Market Scenario
6.6.2.5. Regulatory Framework
6.6.2.6. Reimbursement Scenario
6.6.3. Saudi Arabia
6.6.3.1. Key Country Dynamics
6.6.3.2. Target Disease Prevalence
6.6.3.3. Saudi Arabia Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.3.4. Competitive/Market Scenario
6.6.3.5. Regulatory Framework
6.6.3.6. Reimbursement Scenario
6.6.4. UAE
6.6.4.1. Key Country Dynamics
6.6.4.2. Target Disease Prevalence
6.6.4.3. UAE Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.4.4. Competitive/Market Scenario
6.6.4.5. Regulatory Framework
6.6.4.6. Reimbursement Scenario
6.6.5. Kuwait
6.6.5.1. Key Country Dynamics
6.6.5.2. Target Disease Prevalence
6.6.5.3. Kuwait Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.5.4. Competitive/Market Scenario
6.6.5.5. Regulatory Framework
6.6.5.6. Reimbursement Scenario
6.6.6. Rest of MEA Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Market Participant Categorization
7.2. Key Company Profiles
7.2.1. AbbVie, Inc.
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. Boehringer Ingelheim International GmbH
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Novartis AG
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Regeneron Pharmaceuticals Inc.
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Pfizer, Inc.
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Bristol-Myers Squibb Company
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. F. Hoffmann-La Roche Ltd.
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. UCB S.A.
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Johnson & Johnson Services, Inc.
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. AG Amgen, Inc.
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
7.2.11. Lilly (Eli Lilly and Company)
7.2.11.1. Company overview
7.2.11.2. Financial performance
7.2.11.3. Product benchmarking
7.2.11.4. Strategic initiatives
7.2. Key Company Profiles
7.2.1. AbbVie, Inc.
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. Boehringer Ingelheim International GmbH
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Novartis AG
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Regeneron Pharmaceuticals Inc.
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Pfizer, Inc.
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Bristol-Myers Squibb Company
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. F. Hoffmann-La Roche Ltd.
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. UCB S.A.
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Johnson & Johnson Services, Inc.
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. AG Amgen, Inc.
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
7.2.11. Lilly (Eli Lilly and Company)
7.2.11.1. Company overview
7.2.11.2. Financial performance
7.2.11.3. Product benchmarking
7.2.11.4. Strategic initiatives
List of Tables
Table 1. List of Secondary Sources
Table 2. List of Abbreviations
Table 3. Global rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 4. Global rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 5. North America rheumatoid arthritis therapeutics market, by region, 2018 - 2030 (USD Million)
Table 6. North America rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 7. North America rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 8. U.S. rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 9. U.S. rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 10. Canada rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 11. Canada rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 12. Mexico rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 13. Mexico rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 14. Europe rheumatoid arthritis therapeutics market, by country, 2018 - 2030 (USD Million)
Table 15. Europe rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 16. Europe rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 17. UK rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 18. UK rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 19. Germany rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 20. Germany rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 21. France rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 22. France rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 23. Italy rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 24. Italy rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 25. Spain rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 26. Spain rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 27. Norway rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 28. Norway rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 29. Sweden rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 30. Sweden rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 31. Denmark rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 32. Denmark rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 33. Asia Pacific rheumatoid arthritis therapeutics market, by country, 2018 - 2030 (USD Million)
Table 34. Asia Pacific rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 35. Asia Pacific rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 36. Japan rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 37. Japan rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 38. China rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 39. China rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 40. India rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 41. India rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 42. Australia rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 43. Australia rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 44. South Korea rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 45. South Korea rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 46. Thailand rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 47. Thailand rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 48. Latin America rheumatoid arthritis therapeutics market, by country, 2018 - 2030 (USD Million)
Table 49. Latin America rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 50. Latin America rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 51. Brazil rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 52. Brazil rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 53. Argentina rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 54. Argentina rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 55. Middle East & Africa rheumatoid arthritis therapeutics market, by country, 2018 - 2030 (USD Million)
Table 56. Middle East & Africa rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 57. Middle East & Africa rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 58. South Africa rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 59. South Africa rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 60. Saudi Arabia rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 61. Saudi Arabia rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 62. UAE rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 63. UAE rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 64. Kuwait rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 65. Kuwait rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 2. List of Abbreviations
Table 3. Global rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 4. Global rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 5. North America rheumatoid arthritis therapeutics market, by region, 2018 - 2030 (USD Million)
Table 6. North America rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 7. North America rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 8. U.S. rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 9. U.S. rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 10. Canada rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 11. Canada rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 12. Mexico rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 13. Mexico rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 14. Europe rheumatoid arthritis therapeutics market, by country, 2018 - 2030 (USD Million)
Table 15. Europe rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 16. Europe rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 17. UK rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 18. UK rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 19. Germany rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 20. Germany rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 21. France rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 22. France rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 23. Italy rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 24. Italy rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 25. Spain rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 26. Spain rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 27. Norway rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 28. Norway rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 29. Sweden rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 30. Sweden rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 31. Denmark rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 32. Denmark rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 33. Asia Pacific rheumatoid arthritis therapeutics market, by country, 2018 - 2030 (USD Million)
Table 34. Asia Pacific rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 35. Asia Pacific rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 36. Japan rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 37. Japan rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 38. China rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 39. China rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 40. India rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 41. India rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 42. Australia rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 43. Australia rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 44. South Korea rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 45. South Korea rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 46. Thailand rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 47. Thailand rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 48. Latin America rheumatoid arthritis therapeutics market, by country, 2018 - 2030 (USD Million)
Table 49. Latin America rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 50. Latin America rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 51. Brazil rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 52. Brazil rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 53. Argentina rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 54. Argentina rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 55. Middle East & Africa rheumatoid arthritis therapeutics market, by country, 2018 - 2030 (USD Million)
Table 56. Middle East & Africa rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 57. Middle East & Africa rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 58. South Africa rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 59. South Africa rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 60. Saudi Arabia rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 61. Saudi Arabia rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 62. UAE rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 63. UAE rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
Table 64. Kuwait rheumatoid arthritis therapeutics market, by molecule, 2018 - 2030 (USD Million)
Table 65. Kuwait rheumatoid arthritis therapeutics market, by sales channel, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Rheumatoid arthritis therapeutics market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain-based sizing & forecasting
Fig. 7 QFD modelling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market snapshot
Fig. 10 Molecule and sales channel segment snapshot
Fig. 11 Competitive landscape snapshot
Fig. 12 Global Pharmaceutical Market, (USD billion)
Fig. 13 Market dynamics
Fig. 14 Porter’s five forces analysis
Fig. 15 PESTLE analysis
Fig. 16 Rheumatoid arthritis therapeutics: Molecule outlook and key takeaways
Fig. 17 Rheumatoid arthritis therapeutics market: Molecule market movement analysis
Fig. 18 Biopharmaceuticals market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 Biologics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 TNF-a antagonists market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 T-cell inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 CD20 antigen market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 JAK inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Anti-IL6 biologics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Biosimilars market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 CD20 antigen market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 TNF-a antagonists market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Pharmaceuticals market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 NSAIDs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Analgesics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 DMARDs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Glucocorticoids market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Rheumatoid arthritis therapeutics: Sales channel outlook and key takeaways
Fig. 34 Rheumatoid arthritis therapeutics market: Sales channel market movement analysis
Fig. 35 Prescription market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Over-the-Counter (OTC) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Rheumatoid arthritis therapeutics market revenue, by region, 2023 & 2030 (USD Million)
Fig. 38 Regional marketplace: Key takeaways
Fig. 39 Regional marketplace: Key takeaways
Fig. 40 North America rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Key country dynamics
Fig. 42 U.S. rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 U.S. healthcare system: money flow
Fig. 44 Key country dynamics
Fig. 45 Canada rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 Drug pricing
Fig. 47 Key country dynamics
Fig. 48 Mexico rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 Regulatory framework
Fig. 50 Europe rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Key country dynamics
Fig. 52 UK rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 Key country dynamics
Fig. 54 Germany rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Key country dynamics
Fig. 56 France rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Key country dynamics
Fig. 58 Spain rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 59 Key country dynamics
Fig. 60 Italy rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Key country dynamics
Fig. 62 Denmark rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Key country dynamics
Fig. 64 Sweden rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 65 Key country dynamics
Fig. 66 Norway rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 67 Rest of Europe rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 68 Asia Pacific rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 69 Key country dynamics
Fig. 70 Japan rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 71 Key country dynamics
Fig. 72 China rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 73 China regulatory details
Fig. 74 India rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 75 Key country dynamics
Fig. 76 Australia rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 77 Key country dynamics
Fig. 78 Thailand rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 79 Key country dynamics
Fig. 80 South Korea rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 81 South Korea reimbursement scenario
Fig. 82 Rest of Asia Pacific rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 83 Latin America rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 84 Key country dynamics
Fig. 85 Brazil rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 86 Brazil regulation details
Fig. 87 Brazil reimbursement scenario
Fig. 88 Key country dynamics
Fig. 89 Argentina rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 90 Argentina regulatory framework
Fig. 91 Rest of Latin America rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 92 Key country dynamics
Fig. 93 South Africa rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 94 Key country dynamics
Fig. 95 Saudi Arabia rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 96 Key country dynamics
Fig. 97 UAE rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 98 Key country dynamics
Fig. 99 Kuwait rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2023 (USD Million)
Fig. 100 Rest of MEA rheumatoid arthritis therapeutics market estimates and forecasts,
Fig. 101 Company/competition categorization
Fig. 102 Company market share analysis, 2023
Fig. 103 Strategy mapping
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain-based sizing & forecasting
Fig. 7 QFD modelling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Market snapshot
Fig. 10 Molecule and sales channel segment snapshot
Fig. 11 Competitive landscape snapshot
Fig. 12 Global Pharmaceutical Market, (USD billion)
Fig. 13 Market dynamics
Fig. 14 Porter’s five forces analysis
Fig. 15 PESTLE analysis
Fig. 16 Rheumatoid arthritis therapeutics: Molecule outlook and key takeaways
Fig. 17 Rheumatoid arthritis therapeutics market: Molecule market movement analysis
Fig. 18 Biopharmaceuticals market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 Biologics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 TNF-a antagonists market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 T-cell inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 CD20 antigen market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 JAK inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Anti-IL6 biologics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Biosimilars market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 CD20 antigen market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 TNF-a antagonists market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Pharmaceuticals market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 NSAIDs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Analgesics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 DMARDs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Glucocorticoids market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Rheumatoid arthritis therapeutics: Sales channel outlook and key takeaways
Fig. 34 Rheumatoid arthritis therapeutics market: Sales channel market movement analysis
Fig. 35 Prescription market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Over-the-Counter (OTC) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Rheumatoid arthritis therapeutics market revenue, by region, 2023 & 2030 (USD Million)
Fig. 38 Regional marketplace: Key takeaways
Fig. 39 Regional marketplace: Key takeaways
Fig. 40 North America rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Key country dynamics
Fig. 42 U.S. rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 U.S. healthcare system: money flow
Fig. 44 Key country dynamics
Fig. 45 Canada rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 Drug pricing
Fig. 47 Key country dynamics
Fig. 48 Mexico rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 Regulatory framework
Fig. 50 Europe rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Key country dynamics
Fig. 52 UK rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 Key country dynamics
Fig. 54 Germany rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Key country dynamics
Fig. 56 France rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Key country dynamics
Fig. 58 Spain rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 59 Key country dynamics
Fig. 60 Italy rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Key country dynamics
Fig. 62 Denmark rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Key country dynamics
Fig. 64 Sweden rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 65 Key country dynamics
Fig. 66 Norway rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 67 Rest of Europe rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 68 Asia Pacific rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 69 Key country dynamics
Fig. 70 Japan rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 71 Key country dynamics
Fig. 72 China rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 73 China regulatory details
Fig. 74 India rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 75 Key country dynamics
Fig. 76 Australia rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 77 Key country dynamics
Fig. 78 Thailand rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 79 Key country dynamics
Fig. 80 South Korea rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 81 South Korea reimbursement scenario
Fig. 82 Rest of Asia Pacific rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 83 Latin America rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 84 Key country dynamics
Fig. 85 Brazil rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 86 Brazil regulation details
Fig. 87 Brazil reimbursement scenario
Fig. 88 Key country dynamics
Fig. 89 Argentina rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 90 Argentina regulatory framework
Fig. 91 Rest of Latin America rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 92 Key country dynamics
Fig. 93 South Africa rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 94 Key country dynamics
Fig. 95 Saudi Arabia rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 96 Key country dynamics
Fig. 97 UAE rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 98 Key country dynamics
Fig. 99 Kuwait rheumatoid arthritis therapeutics market estimates and forecasts, 2018 - 2023 (USD Million)
Fig. 100 Rest of MEA rheumatoid arthritis therapeutics market estimates and forecasts,
Fig. 101 Company/competition categorization
Fig. 102 Company market share analysis, 2023
Fig. 103 Strategy mapping
Companies Mentioned
- AbbVie, Inc.
- Boehringer Ingelheim International GmbH
- Novartis AG
- Regeneron Pharmaceuticals Inc.
- Pfizer, Inc.
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- UCB S.A.
- Johnson & Johnson Services, Inc.
- Amgen, Inc.
- Lilly (Eli Lilly and Company)
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | July 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 25.01 Billion |
| Forecasted Market Value ( USD | $ 36.39 Billion |
| Compound Annual Growth Rate | 5.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
